Vanda Pharmaceuticals Inc. (VNDA) Shares Down 2.6%
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares fell 2.6% on Thursday . The stock traded as low as $10.97 and last traded at $10.99, with a volume of 254,726 shares. The stock had previously closed at $11.28.
Several research firms have weighed in on VNDA. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Brean Capital reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, June 6th. Finally, Jefferies Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Friday, June 10th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.92.
The company’s market cap is $486.33 million. The stock’s 50 day moving average price is $11.08 and its 200-day moving average price is $9.15.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.07. During the same period last year, the company posted ($0.10) EPS. The firm had revenue of $33.30 million for the quarter, compared to the consensus estimate of $32.48 million. The business’s revenue was up 50.0% compared to the same quarter last year. On average, analysts expect that Vanda Pharmaceuticals Inc. will post ($0.83) EPS for the current year.
An institutional investor recently raised its position in Vanda Pharmaceuticals stock. J. Goldman & Co LP boosted its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 902,839 shares of the biopharmaceutical company’s stock after buying an additional 151,079 shares during the period. Vanda Pharmaceuticals makes up 0.9% of J. Goldman & Co LP’s portfolio, making the stock its 25th largest position. J. Goldman & Co LP owned about 2.11% of Vanda Pharmaceuticals worth $8,405,000 as of its most recent filing with the SEC.
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.